Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a Phase II trial
- 15 August 2000
- Vol. 89 (4) , 763-768
- https://doi.org/10.1002/1097-0142(20000815)89:4<763::aid-cncr7>3.0.co;2-f
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma?Cancer, 1999
- Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1999
- Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trialEuropean Journal Of Cancer, 1998
- Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinomaCancer, 1998
- Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II studyEuropean Journal Of Cancer, 1996
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomized trialAnnals of Oncology, 1994
- Clinical and preclinical activity of 2′,2′- difluorodeoxycytidine (gemcitabine)Cancer Treatment Reviews, 1993
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958